Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity
Table 1
Demographic data of the COVID-19 patient cohort and control subjects used in the study.
Healthy ()
Moderate ()
Severe ()
Critical ()
Female/male
11/10
27/43
6/10
18/21
Average
Average
Average
Average
Age (general)
46.42
55.67
49.74
50.13
Age (F)
45.4
56.6
49.7
59.4
Age (M)
47.3
54.7
49.7
57
%
%
%
%
Evolution
Medical release
—
—
56
80
15
94
18
46
Death
—
—
12
17
1
6
19
49
Transfer
—
—
2
3
0
0
2
5
Comorbidities
SAH/cardiovascular disorders
—
—
32
28
7
27
26
31
Diabetes mellitus
—
—
19
17
6
23
15
18
Obesity
—
—
8
7
3
11
8
10
Coagulopathies
—
—
1
1
0
0
1
1
Use of alcohol/cigarette
—
—
5
1
0
0
3
4
Serology+HBV HCV
—
—
1
1
0
0
0
0
Liver disorders
—
—
3
3
0
0
2
2
Kidney disorders
—
—
13
12
2
8
5
6
Neurological disorders
—
—
8
7
0
0
3
4
Respiratory disorders
—
—
3
3
1
4
5
6
Metabolic disorders
—
—
13
12
1
4
7
9
Autoimmune disease
—
—
1
1
0
0
0
0
No comorbidity
—
—
5
4
6
23
7
8
Data on age, evolution, and comorbidities of control subjects and COVID-19 patients were classified as moderate, severe, and critical. Legend: M: male; F: female; SC: healthy control; : sample number; SAH: systemic arterial hypertension.
